Azaindole Kinase Modulators for Resistant Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as cancer, fibrosis, and cardiovascular disease involving TGFBR2 and FLT3 kinases with secondary mutations are limited due to resistance to existing kinase inhibitors, necessitating novel compounds that can effectively modulate these kinases.
Innovation Solution
Development of novel 2,5 substituted azaindole compounds and their pharmaceutical compositions that selectively inhibit TGFBR2 and FLT3 kinases, potentially combined with other therapeutic agents, to treat conditions mediated by these kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used to treat diseases involving TGFBR2 and FLT3 kinases, then treatment is provided for common cases, but resistance develops in cases with secondary mutations
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (Formula I with specific substituents R1-R8, m, n) that alter the binding parameters to accommodate secondary mutations in TGFBR2 and FLT3 kinases, thereby maintaining treatment effectiveness where existing inhibitors fail
Solution Approach 2:
The patent employs composite materials by creating hybrid kinase inhibitors that combine features of both type I and type II inhibitors, enabling simultaneous binding to both wild-type and mutated kinase forms, thus providing broad-spectrum coverage against resistant variants
2Measurement precision
If type II kinase inhibitors are used to increase kinase selectivity, then selectivity is improved, but effectiveness against quizartinib-resistant mutants is lost
Solution Approach 1:
The patent applies universality by designing compounds that perform multiple functions: they maintain the selectivity characteristics of type II inhibitors while additionally gaining the ability to inhibit quizartinib-resistant mutants, effectively combining the advantages of both inhibitor types into a single multi-functional agent
3Reliability
If type I inhibitor crenolanib is used to treat quizartinib-resistant D835 mutants, then effectiveness against specific mutants is improved, but activity against other mutant isoforms is insufficient
Solution Approach 1:
The patent applies another dimension by expanding the coverage from single-mutant specificity to broad-spectrum activity across multiple mutant isoforms and wild-type kinases, adding a new dimension of versatility to the inhibitor profile while maintaining effectiveness against previously resistant variants
Data Source
AI summary
Disclosed are compounds having a compound of Formula I:or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, compositions thereof, and uses thereof.